期刊
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
卷 28, 期 -, 页码 -出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/10760296221110568
关键词
anticoagulation; reversal; healthcare resource utilization; cost; idarucizumab; andexanet alfa
资金
- Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
This study assessed the costs and healthcare resource utilization associated with the use of Idarucizumab and Andexanet Alfa for anticoagulant reversal therapy. It found that Idarucizumab was associated with significantly lower hospital and ICU costs, as well as a lower prevalence of intracranial hemorrhage compared to Andexanet Alfa.
Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. Methods: This retrospective study utilizing Premier Healthcare Database (PHD) included patients aged >= 18 years on direct oral anticoagulants (DOACs) who experienced life-threatening bleeds, discharged from the hospital during 5/1/2018-6/30/2019, and received idarucizumab or andexanet alfa. Inverse of treatment probability weighting (IPTW) method was used to balance patient and clinical characteristics between treatment cohorts. Results: Idarucizumab patients were older than andexanet alfa patients (median age 81 vs 77 years; p < 0.001), and less likely to experience intracranial hemorrhage (ICH) (37.1%vs 73.8%; p = 0.001). After IPTW adjustment, idarucizumab patients incurred lower mean total hospital costs ($30,413 +/- $33,028 vs $44,477 +/- $30,036; p < 0.001),and mean intensive care unit (ICU) cost ($25,114 +/- $30,433 vs $43,484 +/- $29,335; p < 0.001). Conclusions: Anticoagulant reversal therapy with idarucizumab was associated with significantly lower adjusted mean total hospital and ICU costs compared with andexanet alfa. However, a higher prevalence of ICH bleeds was noted in the andexanet alfa group.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据